Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.57 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.56 |
| ▸ | FLT3 | P36888 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 9/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 5/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366280 | 0.93 | MET (0.55) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL13861030 | 0.92 | AXL (0.49) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL13861117 | 0.92 | KDR (0.49) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL14366268 | 0.92 | MET (0.69) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL4333630 | 0.88 | AXL (0.54) | METPDGFRBFLT3KDRAXL | |
| SCHEMBL13861024 | 0.86 | AXL (0.51) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL4334017 | 0.85 | MET (0.59) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL13861116 | 0.85 | KDR (0.47) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL13861398 | 0.85 | MET (0.61) | METCSF1RPDGFRBPDGFRAFLT3 | |
| SCHEMBL4344097 | 0.84 | MET (0.57) | METCSF1RPDGFRBPDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | MET 2/4885CSF1R 29/4885PDGFRB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.